Introduction
Helicobacter pylori eradication has led to a significant decrease in the incidence of gastric cancer and can prevent its progression. 1, 2 The H. pylori eradication regimens established in the Asia-Pacific region and three countries in East Asia (Japan, South Korea, and China) have been summarized in the recent guidelines. [3] [4] [5] [6] Nevertheless, resistance to clarithromycin, which is included in the first-line therapy for H. pylori, has recently emerged in several regions across the globe. [7] [8] [9] [10] In addition, resistance to alternative regimens including metronidazole was significantly associated with their submit your manuscript | www.dovepress.com
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Miftahussurur et al frequent use. 9, 11 Moreover, high levofloxacin resistance was reported in several countries in Asia, and this even reached a rate of up to 67%. 9, [11] [12] [13] [14] [15] Based on the Maastricht Consensus V, a suitable first-line regimen is considered to be effective against H. pylori if the cure rate is >90%, 16 and thus, it can prevent secondary antibiotic resistance. However, further investigation is warranted to assess the antibiotic sensitivity of H. pylori to overcome the multiple treatment failures, with H. pylori eradication failure in >20% of cases, in specific countries to determine the best rescue treatment regimens. 17 Indonesia, located in Southeast Asia, is the fourth most populous country in the world, with a total population of ~260 million in 2017, which is composed of various ethnic groups. Java, Sumatra, Papua, Kalimantan, and Sulawesi Island are the five main islands, with half of the total population living on Java Island. Similar to other regions in Indonesia, we previously reported high resistance to clarithromycin (21.4%) on Java Island, the rate of which is more than the limit of 15% recommended by the Maastricht consensus. 18 In addition, the resistance rates to metronidazole and levofloxacin in Indonesian H. pylori strains are high (46.8% and 31.2%, respectively). Importantly, the prevalence of H. pylori infection in Indonesians, particularly among the major ethnic group of Javanese, is low (2.4%), 19 highlighting the difficulties in isolating strains and conducting clinical trials on H. pylori eradication in Indonesia. In addition, although dyspepsia is the fifth most common symptom in an inpatient setting in Indonesia, the availability of gastrointestinal endoscopy is limited, and it is predominantly utilized on Java Island. 20 Among the several antibiotics proposed as alternative regimens for H. pylori is furazolidone, a synthetic nitrofuran with broad-spectrum antimicrobial activity that blocks bacterial metabolism by interfering with bacterial oxidoreductase activity. [21] [22] [23] [24] [25] Furthermore, in a study, the sensitivity of H. pylori to rifabutin and the utility of rifabutin as a rescue regimen following treatment failure with other antibiotics were reported in >50% of the subjects. 26 Rifabutin is an antituberculosis agent which acts on DNA-directed RNA polymerase and inhibits transcription in H. pylori. [27] [28] [29] Rifaximin is a semisynthetic derivate of rifamycin with antimicrobial activities against a broad spectrum of organisms, including H. pylori, is not absorbed in the gastrointestinal tract, and associated with mutations in rpoB. 30 Conversely, garenoxacin and sitafloxacin, two novel quinolones, were proposed to treat H. pylori-resistant strains harboring gyrA mutation. 31 In this study, we examined the resistance profile of H. pylori to several antibiotics used as alternative regimens in a geographical area with a high prevalence of clarithromycinand metronidazole-resistant H. pylori strains. Our findings suggest several potential regimens that might overcome the hurdle of clarithromycin and metronidazole resistance, and the results might be of value not only for Indonesia but also for countries worldwide. Furthermore, we identified several point mutations in H. pylori that might confer rifaximin resistance.
Materials and methods
Patients and H. pylori
This nationwide study included 1,039 adult dyspeptic patients who underwent endoscopic biopsy between August 2012 and February 2016 in 18 cities on eight Indonesian islands. Among these 1,039 patients, 752 were reported in a previous study. 18 Gastric biopsy specimens of the remaining 287 patients used in the current study ( Figure 1) were obtained from the following regions: Cimacan (n=22) and Surabaya (n=22) on Java Island; Padang (n=33), Palembang (n=38), and Dolok Sanggul (n=47) on Sumatera Island; Gunungsitoli (n=32) on Nias Island; Kolaka (n=50) on Sulawesi Island; and Merauke (n=43) on Papua Island. There were 599 males (age range, 17-88 years; mean, 46.14±13.63 years) and 439 females (age range, 14-80 years; mean, 47.79±14.4 years). Patients with bleeding due to esophageal varices, those with a history of partial gastric resection, and those with a history of successfully eradicated H. pylori infection were excluded.
Figure 1
The chart showing the enrollment of patients in the current study. Note: *One strain (Malang1) could not grow well, and hence, we excluded it from the study.
All enrolled patients N=1,039
Reported in our previous study N=752
Successfully cultured N=77
Successfully cultured N=29 
antibiotic susceptibility testing
The twofold agar dilution method was used to determine minimum inhibitory concentrations (MICs) of furazolidone (Tokyo Chemical Company, Tokyo, Japan), rifaximin (Tokyo Chemical Company), rifabutin (Sigma-Aldrich Co., St. Louis, MO, USA), garenoxacin (Sigma-Aldrich Co.), and sitafloxacin (Haoyuan Chemexpress, Shanghai, China) according to M07-A9 version of methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically (approved standard, Clinical and Laboratory Standard Institute). Briefly, the isolates were subcultured on Mueller-Hinton II agar supplemented with 10% horse blood. The bacteria were diluted in Brucella broth and adjusted to be equivalent to a McFarland opacity standard of 0.5. The prepared bacterial suspension (1 µL) was then inoculated using 2 mm-pin inoculator (Tokken Inc. Chiba, Japan) on Mueller-Hinton II agar supplemented with 5% horse blood. The MICs were determined after a 72-hour incubation. An H. pylori strain from American Type Culture Collection (catalog # 43504) was used as the quality control. Resistance breakpoints were determined based on an MIC of >4 mg/L for furazolidone and rifaximin and >1 mg/L for rifabutin, garenoxacin, and sitafloxacin, as described previously. [32] [33] [34] [35] The final concentrations of furazolidone and rifaximin ranged from 0.25 to 32 µg/mL, while those of rifabutin, garenoxacin, and sitafloxacin ranged from 0.064 to 8 µg/mL.
Detection of virulence factors and resistant strains
H. pylori DNA was extracted using the commercially available DNeasy ® kit (Qiagen, Hilden, Germany) and stored at −20°C until further analysis. Data on the gyrA and gyrB mutations in H. pylori were available for the 752 patients who were reported in our previous publication. 18 In addition, mutation analyses were performed for gyrA and gyrB mutation status in the remaining 287 specimens. Furthermore, next-generation sequencing (MiSeq next-generation sequencer; Illumina, San Diego, CA, USA) was used to analyze all specimens for full-length rpoB, oipA status ("on" or "off "), and the presence of vacA (s1 or s2; m1 or m2; and i1, i2, or i3), iceA (iceA1 or iceA2), jhp0562, and b- (1, 3) galT genotypes of the Indonesian strains. The BLAST algorithm implemented in the CLC Genomics Workbench software (ver. 11; Qiagen NV, Venlo, Netherlands) was used for the analysis. The sequences of hp0701, hp0501, hp1198, and hp0638 of the strain 26695 (GenBank accession number AE000511.1) were used as queries to obtain the gyrA, gyrB, rpoB, and oipA sequences, respectively, from the Indonesian next-generation sequencing data. The variants related to antibiotic resistance were predicted by comparing all the rpoB sequences of resistant strains and five random sensitive strains with the rpoB sequence of the strain 26695 for rifaximin resistance and gyrA and gyrB for garenoxacin and sitafloxacin resistance. Briefly, after obtaining the rpoB, gyrA, and gyrB sequences and confirming the absence of insertions or deletions leading to frameshift mutations, the sequences were aligned at the codon level using the MAFFT software (http://mafft.cbrc.jp/alignment/server/). Subsequently, each codon of the resistant and sensitive strains was compared to the reference sequence using our original PERL script and confirmed by visual inspection. Variants found in both the resistant and the sensitive strains were considered as normal variants and were excluded from further analysis. Variants found in the resistant strains but not in the sensitive ones were considered as variants related to antibiotic resistance.
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Discrete variables were analyzed by the chi-squared test, whereas interval/ratio variables were analyzed using Student's t-test or the Mann-Whitney U test. P values of <0.05 were considered statistically significant. All statistical analyses were performed using the SPSS statistical software package version 18.0 (SPSS Inc., Chicago, IL, USA).
Results
Resistance of H. pylori to alternative antibiotics
Twenty-nine H. pylori strains were isolated from 287 patients including 1, 1, 10, 1, 7, and 9 strains from Surabaya, Palembang, Dolok Sanggul, Gunungsitoli, Kolaka, and Merauke, respectively. No H. pylori strains could be isolated from the specimens obtained from the patients in Cimacan and Padang. We also reanalyzed the 77 strains that were assessed for their sensitivity to clarithromycin, amoxicillin, metronidazole, tetracycline, and levofloxacin in our previous study. 18 However, one of these strains (Malang1) did not grow properly. Therefore, a total of 105 strains were analyzed in the current study.
Overall, more than half of the strains (61/105, 58.1%) were sensitive to all five antibiotics examined in this study. Forty strains were resistant to rifaximin (38.9%; Table 1 ). In addition, the rate of garenoxacin resistance was 6.7% (7/105). In contrast, none of the examined strains exhibited resistance to furazolidone, rifabutin, or sitafloxacin. Four strains were resistant to two antibiotics. The rates of resistance to rifaximin and garenoxacin were higher in males than in females (28/ [5.2%], respectively), although these differences were not statistically significant (P=0.28 and P=0.65, respectively). The antibiotic-resistant strains were more frequent among those older than 30 years of age, albeit in the absence of a significant association. Overall, 95, 1, and 9 antibioticresistant strains were isolated from patients with chronic gastritis, gastric cancer, and peptic ulcer, respectively. The rate of garenoxacin resistance was higher in the patients with chronic gastritis than in those with peptic ulcer (6/95 [6.3%] vs 0/9 [0.0%]; P=0.001)
Rates of antibiotic resistance according to location and ethnicity
The rate of garenoxacin resistance was highest among the H. pylori strains obtained from Java Island compared to those from the other regions (15.4% vs 10.0%, 6.2%, and 4.7% from the Sumatera, Papua, and Sulawesi Island, respectively; Table 2 ). The garenoxacin resistance was not detected in any of the strains from Kalimantan, Timor, and Bali. In contrast, more than half of the strains isolated from the specimens of patients from Kalimantan, Sulawesi, and Bali Islands had rifaximin resistance (60.0%, 52.4%, and 50.0%, respectively). Finally, the rate of rifaximin resistance was at least 20% in all the study locations.
The analysis of the rates of antibiotic resistance according to ethnicity revealed that the garenoxacin resistance rate of 20% was higher in the strains isolated from the Chinese Indonesian patients than in those isolated from the Bataknese, Buginese, and Papuan patients (9.6%, 7.7%, and 6.2%, respectively; Table 3 ); however, this difference was not statistically significant (P=0.44, P=0.33, and P=0.31, respectively). None of the 
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Miftahussurur et al strains isolated from the Ambonese, Balinese, Dayak, Javanese, Minahasanese, and Timor patients exhibited garenoxacin resistance, indicating that the bacterial strains in the patients belonging to these ethnic groups were sensitive to furazolidone, rifabutin, garenoxacin, and sitafloxacin but not rifaximin. Only one strain from a Javanese patient (only one strain was isolated) was sensitive to all five antibiotics. Rifaximin resistance was distributed evenly among ethnic groups ( 
comparison of alternative and standard antibiotic regimens
We determined the rates of resistance of the 76 H. pylori strains reported in our previous study 14 to the five antibiotics and compared them with the rates of resistance to the standard antibiotics used for H. pylori infection (Table 4) . Our findings above indicated that, except for rifaximin with a resistance rate of 35.5% (27/76), there was a possibility that the remaining four antibiotics might overcome the high rate of resistance to levofloxacin and metronidazole. Interestingly, H. pylori in the regions with high rates of clarithromycin resistance, such as Bali and Papua Islands (1/6, 16.7% and 1/7, 14.3%, respectively), was still sensitive to garenoxacin, although this finding could be due to the low number of strains with clarithromycin resistance. In contrast, the isolate from Java Island with the highest rate of clarithromycin resistance also exhibited a high rate of rifaximin resistance. Thus, we suggest that rifaximin should not be considered as an alternative in areas with high clarithromycin resistance. Garenoxacin may combat H. pylori in regions with high amoxicillin resistance such as Papua Island (0.0% vs 14.3% of resistance rate for garenoxacin and amoxicillin, respectively) but not in regions with high tetracycline resistance such as Java Island (both 15.4% of resistance rate) ( Table 4) .
To further analyze the associations among resistance rates of metronidazole, levofloxacin, garenoxacin, and rifaximin, we created a two-by-two table (Figure 2 ). Only seven strains (9.2%) exhibited resistance to both rifaximin and levofloxacin. 
Mutations associated with garenoxacin resistance
We analyzed the gyrA and gyrB mutations from the two strains with high MICs for garenoxacin identified in the current study (Merauke20 and Kolaka72; Table 5 ) together with those identified in our previous study. 18 Four strains with the highest MICs for garenoxacin (2 mg/L) were associated with a high MIC for levofloxacin (>32 mg/L). In addition, three of these strains had an amino acid substitution at Asp91 or Asn87 in the GyrA, which were predominantly associated with the highest MICs for levofloxacin. 18 However, the 13 garenoxacin-sensitive strains with low MIC values (<0.063-0.5 mg/L) were also associated with those mutations, suggesting an inconsistent effect of these mutations. Moreover, none of the garenoxacin-resistant strains harbored a substitution at Arg484 or Ser479 of the gyrB. Finally, none of the strains harbored parC or parE, the two important genes associated with quinolone resistance in other bacteria.
Mutations associated with rifaximin resistance
We analyzed full-length rpoB from 40 rifaximin-resistant strains based on the next-generation sequencing data, with an Notes: an MIc >1 mg/L was used as a resistance breakpoint for levofloxacin, garenoxacin, and sitafloxacin.
a One of the previously isolated strains could not sustain growth. b The new strains with high MIC of garenoxacin that were not reported in our previous study. Abbreviation: GAR, garenoxacin; LVX, levofloxacin; MIC, minimum inhibitory concentration; na, not available; SIT, sitafloxacin.
Virulence factors and antibiotic resistance types
In addition to the data on virulence factors that we reported previously, 18 
Discussion
The current study revealed that none of the H. pylori strains isolated from Indonesian patients were resistant 3  Jayapura06  8  L547F, K786R, I837V, A964T, V1275I, A1533S, P1623S, D1697N, G1908E, A2099T, S2640Y  4  Jakarta9  4  I64V, L295I, S355Y, V657I, T1023I, S1197A, Q2042R, K2068R  5  Kupang10  4  G523C, I832V, E877K, K1006E, E1528D, Q1666H, N1944S, A2255V, G2512S, S2619I, V2774M  6  Kupang23  4  L169S, S355H, A693T, I837V, K854R, L977I, I1351T, N1999H, K2068R, Q2079K, S2415N, I2481V,  V2528L, P2679S, M2696T  7  Kupang26  4  L169A, S355H, I837V, L977I, N1999H, Q2079K, S2415N, A2472V, I2481V, V2528L, P2679S, M2696T  8  Kupang29  4  K42R, I748V, T773I, A958T, E969D, S986G, A1025V, V1052I, V1122I, A2414V, S2619I  9  Kupang30  4  S355H, S627N, I837V, A1025V, D1162N, K1165R, L1401I, R1711H, Q2079K, A2234T, D2380E  10  Kupang34  4  S355H, A732V, I837V, V955I, L977I, V1028A, N1999H, K2068R, Q2079K, S2415N, I2481V, to furazolidone, suggesting that furazolidone might be considered as an alternative H. pylori treatment regimen in Indonesia, especially in regions with high prevalence of strains exhibiting dual resistance to clarithromycin and metronidazole. 36 Our results are in agreement with those reported by a study from a neighboring country, Malaysia, 
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Miftahussurur et al which also found that all the isolated strains were sensitive to furazolidone. 37 Furazolidone use has been proposed in recent guidelines for H. pylori management in developing countries, due to its efficacy, low rate of primary bacterial resistance, and lack of alternative and low-cost therapies. 38, 39 To improve the H. pylori cure rates, bismuth should be added to therapy. For example, the addition of bismuth to quadruple therapy including furazolidone has been successful in China, with cure rates reaching 92.26% with minimal side effects. 40 However, bismuth is unavailable in certain regions 41 due to potential bismuth-associated carcinogenic effects, including mutagenicity and genotoxicity in in vitro and animal models, 42, 43 and it was classified as a type III carcinogen for humans in 1997 by the International Agency on Research on Cancer. Furthermore, there are currently no standardized rescue therapies available for patients who fail the initial furazolidone-based treatment.
Our finding of all isolated strains exhibiting rifabutin sensitivity provides support for rifabutin as a potential alternative antibiotic against H. pylori. The concentrations of rifabutin in the gastric juice were reported to be 10-17 times higher than in peripheral blood. 44 The antibacterial activity of rifabutin, which is not affected by the low pH environment in the stomach, is higher than that of rifampicin. 27 Importantly, its target is different from that of clarithromycin. Therefore, its efficacy in strains with primary clarithromycin resistance, even in those who are also resistant to metronidazole, is high, 45, 46 although the majority of the clinical trials that define these differences were conducted in Western countries. Nonetheless, the adverse effects of rifabutin such as myelotoxicity should be considered. Furthermore, the increased use of rifabutin in Indonesia, a country with high tuberculosis prevalence, might lead to rifabutin resistance of Mycobacterium tuberculosis. Several studies reported substantial in vitro cross-resistance to rifampicin, a main component of the tuberculosis therapy regimens, although rifabutin resistance in H. pylori in in vitro was rarely reported. 28 A history of rifampicin treatment should be taken into consideration before prescribing rifabutin for H. pylori eradication to reduce the possibility of failure of tuberculosis treatment and H. pylori eradication. Importantly, rifabutin use in combination with clarithromycin should be avoided, based on evidence showing the inhibition of rifabutin metabolism by clarithromycin in liver microsomes, 47 which suggests that potential toxicity might arise with combination use.
Compared with the other fluoroquinolones, sitafloxacin is a more potent inhibitor of DNA gyrase and topoisomerase IV, which play important roles in bacterial DNA repair, transcription, replication, and recombination. 48 Sitafloxacin improves the efficacy of quinolone-based rescue therapy by virtue of its ability to eradicate H. pylori strains with gyrA mutations. 49 However, limited access and availability are the main concerns regarding sitafloxacin. Currently, Japan and Thailand are the only countries that provide sitafloxacin in their health care system, and clinical trials for sitafloxacin are underway in Western countries. 50 In contrast, although garenoxacin was also reported to eradicate H. pylori strains with gyrA mutations, 51 there were several strains that were resistant to this antibiotic in the current study. Interestingly, the MIC value of levofloxacin was not associated with MIC value of garenoxacin. For example, although all seven garenoxacin-resistant strains exhibited the highest MICs for levofloxacin (>32 mg/L), all ten strains with the highest levofloxacin MIC were sensitive to garenoxacin. The lower antibacterial activity of garenoxacin against H. pylori compared with that of sitafloxacin might be associated with the high affinity of sitafloxacin to DNA gyrase. 52 Due to high levofloxacin resistance rates in Indonesia, our finding should be instrumental in formulating second-line regimen guidelines to eradicate H. pylori.
One study found that double mutations in gyrA were associated with a sevenfold increase in sitafloxacin MIC compared with the pretreatment MICs and that double mutations in gyrA, including the mutations at Asp91 and Asn87, were associated with eradication failure. 53 We found that double mutations were not associated with an increase in the MIC of sitafloxacin, although none of the strains harbored both Asp91 and Asn87 mutations. Similar to sitafloxacin, none of the single or double mutations in GyrA or GyrB were associated with garenoxacin resistance. Although parC and parE are important genes associated with quinolone resistance, none of the isolated H. pylori strains exhibited the presence of/ expressed these genes, as previously described. 54 Our results suggest that genes other than gyrA or gyrB were associated with resistance to sitafloxacin and garenoxacin, which should be investigated in future studies.
Among the several alternative drugs tested in the current study, the rate of resistance was highest to rifaximin; this finding is in agreement with a previous study showing that rifaximin-based triple therapy did not achieve acceptable H. pylori cure rates. 55, 56 However, rifaximin is a promising H. pylori drug due to poor absorbance in the blood, which can minimize adverse effects, and its higher bioavailability in the gastrointestinal tract than that of other antibiotics. 57 The poor eradication rates might be due to a failure in achieving sufficient therapeutic concentrations under and within the submit your manuscript | www.dovepress.com
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Miftahussurur et al gastric mucosal layer, which is a frequent site of H. pylori colonization. 58 Therefore, well-designed clinical trials are necessary to evaluate rifaximin efficacy against H. pylori, including high-dose regimens of longer duration, additional bioadhesive formulations, and combinations with mucolytic agents for persistent coverage of the gastric mucosa. 58 Although rpoB mutations were reported to play a role in rifaximin resistance in other bacteria such as Escherichia coli, 59 Clostridium difficile, 60, 61 Staphylococcus, 62 and M. tuberculosis, 63 only one study found an association between codons 524-545 and 585 of rpoB with rifabutin resistance in H. pylori. 30 In the current study, we found numerous missense mutations in rpoB of rifaximin-resistant strains, including novel and predominant mutations: 837I, 2414A, 2079K, and 2068K. Although the mechanism remains unclear, the risk for horizontal transmission of the rpoB mutations is lower than that of a resistance gene located on a plasmid or transposon; however, certain yet-to-be determined conditions and improper prescription or usage of antibiotic could still facilitate the rapid transmission of such mutations. 62 Strict control should be practiced to prevent rifaximin failure in H. pylori eradication.
The major limitation of this study was the relatively small number of samples, and when we divided the samples based on regions, it yielded very low sample number in each region. Therefore, it may be difficult to represent H. pylori strains in whole Indonesia. Further study with a bigger sample size is necessary. However, these samples, obtained from 1,039 endoscopic patients, comprised the biggest cohort of H. pylori strains isolated in Indonesia thus far. Indonesia is a wide country and consists of many ethnic groups. Among those, some ethnic groups had a much higher prevalence of H. pylori infection than the others; however, the overall gastric cancer risk in Indonesia is low, suggesting that Indonesia may become the best example for Asian enigma similar to South Asia. In addition, only a fraction of the genomic changes that were related to drug resistance, among a total of 1,600 genes of H. pylori, were examined in the current study. Although sitafloxacin is a potent drug for H. pylori, it has not been approved by the Indonesian National Agency of Drug and Food Control. Thus, sitafloxacin-based regimens cannot be currently prescribed in Indonesia.
Conclusion
Furazolidone-, rifabutin-, and sitafloxacin-based therapies should be considered as alternative regimens to eradicate H. pylori in Indonesia, including regions with high rates of metronidazole and clarithromycin resistance. Moreover, sitafloxacin but not garenoxacin could inhibit the levofloxacin-resistant H. pylori strains.
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